-
Novartis NYSE:NVS Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Location: Lichtstrasse 35, Basel, 4056, Switzerland | Website: https://www.novartis.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
238.9B
Cash
7.137B
Avg Qtr Burn
N/A
Short % of Float
0.25%
Insider Ownership
0.00%
Institutional Own.
7.16%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Vanrafia® (atrasentan) Details Proteinuria reduction in primary IgA nephropathy (IgAN) | Approved Update | |
Fabhalta® (iptacopan) Details IgA nephropathy, Kidney disease | Approved Quarterly sales | |
Kisqali® (ribociclib) + endocrine therapy (ET) Details Breast cancer, Cancer | Approved Quarterly sales | |
SCEMBLIX Details Chronic myelomonocytic leukemia, Blood cancer, Cancer, Leukemia | Approved Quarterly sales | |
Fabhalta® (iptacopan) Details Kidney disease, C3 Glomerulopathy | PDUFA Adcomm | |
Remibrutinib [BTK inhibitor] Details Chronic spontaneous urticaria | NDA Submission | |
BION-1301 (Zigakibart) Details IgA nephropathy | Phase 3 Data readout | |
Fabhalta® (iptacopan) Details Paroxysmal nocturnal hemoglobinuria | Phase 3 Data readout | |
Leqvio (inclisiran) Details Atherosclerotic cardiovascular disease | Phase 3 Update | |
Tafasitamab (CD19) Details Cancer, B-cell malignancies, Marginal zone lymphoma, Follicular lymphoma | Phase 3 Update | |
Lutathera® Details Gastroenteropancreatic neuroendocrine tumors, Cancer | Phase 3 Update | |
Intrathecal onasemnogene abeparvovec (OAV101 IT) Details Kidney disease, Glomerular diseases, IgA nephropathy | Phase 3 Update | |
Coartem® (artemether- lumefantrine) Details Malaria, Viral infection | Phase 2/3 Update | |
Atrasentan Details Glomerular diseases, Kidney disease | Phase 2 Data readout | |
CHK-336 Details Primary hyperoxaluria | Phase 1 Update |